Heart Failure System Significantly Reduced 30-Day Hospital Readmission Rates
St. Paul, MN - St. Jude Medical, Inc., yesterday announced a retrospective data analysis from the CHAMPION clinical trial showing a significant reduction in 30-day hospital readmission rates for patients age 65 and older. The CHAMPION trial looked at the safety and effectiveness of the CardioMEMS™ HF System for patients with New York Heart Association (NYHA) Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months. The analysis — Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalization and All-Cause 30-Day Readmissions in Medicare-Eligible patients with NYHA Class III Heart Failure — was presented during the American Heart Association Scientific Sessions.
This analysis looked at patients 65 and older (Medicare-eligible) from the CHAMPION trial and found that there was a 58 percent reduction in all-cause hospital readmissions (hospitalization for any reason) and a 78 percent reduction in HF hospital readmissions when patients were managed with the CardioMEMS HF System compared to standard-of-care medical management. These findings suggest that use of the CardioMEMS HF System can significantly reduce the hospital’s risk of government-imposed penalties that are designed to reduce patient readmissions within 30 days of treatment. Continue>
Posted in: Featured Technology | December 9, 2016
Posted in: Featured Technology | May 22, 2014
Posted in: Featured Technology | May 15, 2015